Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 7/20 | 0.69 |
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30383954 | 1.00 | KEAP1 (0.69) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL25198003 | 1.00 | KEAP1 (0.69) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL30382772 | 0.91 | KEAP1 (0.56) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL25196048 | 0.91 | KEAP1 (0.56) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL25205904 | 0.90 | KEAP1 (0.55) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL30383426 | 0.90 | KEAP1 (0.55) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL25207556 | 0.86 | ALDH1A1 (0.68) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL31233380 | 0.85 | FKBP1A (0.56) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL25189629 | 0.84 | KEAP1 (0.67) | KEAP1NFE2L2KDM4EALDH1A1MAPT | |
| SCHEMBL25212469 | 0.84 | KEAP1 (0.67) | KEAP1NFE2L2KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | KEAP1 210/4885NFE2L2 730/4885KDM4E 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.